Home  »  Finance   »  Viking Therapeutics Inc. (NASDAQ: VKTX) Stock: Loo...

Viking Therapeutics Inc. (NASDAQ: VKTX) Stock: Looks Like A Good Investment

Viking Therapeutics Inc. (NASDAQ:VKTX) shares, rose in value on Thursday, 08/04/22, with the stock price up by 11.58% to the previous day’s close as strong demand from buyers drove the stock to $3.18.

Actively observing the price movement in the last trading, the stock closed the session at $2.85, falling within a range of $2.86 and $3.195. The value of beta (5-year monthly) was 1.44. Referring to stock’s 52-week performance, its high was $7.20, and the low was $2.02. On the whole, VKTX has fluctuated by 2.91% over the past month.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

With the market capitalization of Viking Therapeutics Inc. currently standing at about $257.68 million, investors are eagerly awaiting this quarter’s results, scheduled for Nov 01, 2022 – Nov 07, 2022.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VKTX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a Hold.

10 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 9 recommend it as a Buy and 1 called the VKTX stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VKTX currently trading nearly -5.23% and 13.12% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 51.80, while the 7-day volatility ratio is showing 12.10% which for the 30-day chart, stands at 8.67%. Furthermore, Viking Therapeutics Inc. (VKTX)’s beta value is 1.43, and its average true range (ATR) is 0.28. The company’s stock has been forecasted to trade at an average price of $17.56 over the course of the next 52 weeks, with a low of $10.00 and a high of $30.00. Based on these price targets, the low is -214.47% off current price, whereas the price has to move -843.4% to reach the yearly target high. Additionally, analysts’ median price of $15.00 is likely to be welcomed by investors because it represents a decrease of -371.7% from the current levels.

A comparison of Viking Therapeutics Inc. (VKTX) with its peers suggests the former has fared considerably weaker in the market. VKTX showed an intraday change of 11.58% in last session, and over the past year, it shrunk by -45.64%%. In comparison, Societal CDMO Inc. (SCTL) has moved higher at 14.43% on the day and was down -40.00% over the past 12 months. On the other hand, the price of Ultragenyx Pharmaceutical Inc. (RARE) has risen 4.05% on the day. The stock, however, is off -34.73% from where it was a year ago. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.08%. Meanwhile, the Dow Jones Industrial Slipped by -0.26%.

Data on historical trading for Viking Therapeutics Inc. (NASDAQ:VKTX) indicates that the trading volumes over the past 10 days have averaged 1.0 million and over the past 3 months, they’ve averaged 1.17 million. According to company’s latest data on outstanding shares, there are 76.84 million shares outstanding.

Nearly 0.10% of Viking Therapeutics Inc.’s shares belong to company insiders and institutional investors own 41.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.45 million shares as on Jul 14, 2022, resulting in a short ratio of 1.61. According to the data, the short interest in Viking Therapeutics Inc. (VKTX) stood at 3.16% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 4.6 million. The stock has fallen by -30.87% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VKTX stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]